The Science Behind Biologics and Biosimilars
Kelley D. Mayden, MSN, FNP, AOCNP
Wellmont Cancer Institute
The introduction of biologics into oncology has been groundbreaking. At a time when many of the “innovator drug” patents expire the new frontier is becoming biosimilars. Unlike established medications, biosimilars and biologics are not chemically synthesized. This activity explains fundamental differences in the complexity of biosimilars, nomenclature, prescribing, documentation and patient education/consent – indispensable information for the oncology AP.
These CME/CE/CPE accredited activities are jointly provided by